Priority Review
Also known as: Priority review designation, Expedited review, Fast review, 6-month review
Priority Review is an FDA designation that shortens the standard drug review period from approximately 10 months to 6 months for medications that offer significant improvements in the treatment, prevention, or diagnosis of serious conditions. This expedited review does not change approval standards but accelerates the timeline for FDA decision-making.
Last updated: February 1, 2026
How Priority Review Works
Eligibility Criteria
A drug qualifies for priority review if it treats a serious condition and demonstrates:
| Criterion | Description |
|---|---|
| Significant improvement | Substantial advance over existing therapies |
| Serious condition | Disease with substantial impact on daily functioning |
| Treatment advance | Better efficacy, safety, or patient convenience |
What Counts as Significant Improvement
- Greater effectiveness than available therapies
- Fewer or less serious side effects
- Better patient compliance potential
- Effectiveness in patients who don’t respond to existing treatments
- New mechanism addressing unmet need
Review Timeline Comparison
Standard vs Priority Review
| Aspect | Standard Review | Priority Review |
|---|---|---|
| Target timeline | 10 months | 6 months |
| PDUFA goal date | 10 months from filing | 6 months from filing |
| Evidence required | Same | Same |
| Approval standards | Full | Full |
| Resources allocated | Standard | Enhanced |
Important Clarification
Priority review does NOT mean:
- Lower evidence standards
- Automatic approval
- Reduced safety requirements
- Abbreviated clinical trials
It simply means FDA commits more resources to review the application faster.
FDA Expedited Programs Comparison
Four Distinct Designations
| Program | Primary Benefit | When Determined |
|---|---|---|
| Fast Track | More frequent FDA meetings, rolling review | Early development |
| Breakthrough Therapy | Intensive FDA guidance, organizational commitment | Phase 2 |
| Accelerated Approval | Approval on surrogate endpoint | NDA submission |
| Priority Review | Shorter review timeline | NDA submission |
Combinations Are Common
Drugs often receive multiple designations:
- Fast Track + Priority Review
- Breakthrough + Accelerated Approval + Priority Review
- A single drug can potentially receive all four
Relevance to Peptide Therapies
GLP-1 Agonist Priority Reviews
| Drug | Indication | Received Priority Review |
|---|---|---|
| Semaglutide (Wegovy) | Chronic weight management | Yes |
| Tirzepatide (Zepbound) | Chronic weight management | Yes |
| Semaglutide (Ozempic) | Type 2 diabetes | Standard review |
| Liraglutide (Saxenda) | Weight management | Yes |
Why Obesity Indications Received Priority
- Obesity recognized as serious chronic disease
- Significant efficacy improvement over existing options
- Major unmet medical need
- Substantial impact on patient health outcomes
Priority Review Vouchers
Incentive System
FDA grants transferable priority review vouchers for:
- Rare pediatric diseases
- Tropical diseases
- Medical countermeasures
Companies can use or sell these vouchers to obtain priority review for any drug application, even one that wouldn’t otherwise qualify.
Voucher Economics
| Aspect | Details |
|---|---|
| Value | $100+ million (market varies) |
| Transferable | Yes - can be sold to other companies |
| Purpose | Incentivize neglected disease development |
| Impact | 4-month faster potential market access |
Impact on Drug Development
For Pharmaceutical Companies
- Earlier market entry (4 months revenue advantage)
- Reduced time to recoup R&D investment
- Competitive advantage over similar drugs
- Enhanced investor confidence
For Patients
- Faster access to new treatment options
- Earlier availability of improved therapies
- Continued rigorous safety review
- No compromise on approval standards
Frequently Asked Questions
Does priority review mean a drug is better?
Not necessarily. Priority review indicates FDA recognizes potential for significant improvement, but the same evidence standards apply. Many excellent drugs receive standard review because they treat less serious conditions or offer incremental rather than substantial improvements.
How often does FDA grant priority review?
Approximately 40-50% of novel drug approvals receive priority review. The percentage varies by therapeutic area, with oncology and rare diseases having higher rates.
Can a drug be denied approval after priority review?
Yes. Priority review affects timing, not outcome. FDA can and does issue complete response letters (essentially denials) to priority review applications that don’t meet approval standards. The same rigorous evaluation occurs regardless of review designation.
Related Peptides
Related Terms
Disclaimer: This glossary entry is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical questions.